Know Cancer

forgot password

A Biomarker-Integrated Study in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

18 Years
Open (Enrolling)
Lung Cancer

Thank you

Trial Information

A Biomarker-Integrated Study in Chemorefractory Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

This study is the "umbrella" or screening study in a group of 5 studies known as the BATTLE
(Biomarker-integrated Approaches of Targeted Therapy of Lung Cancer Elimination) program.
In order to participate in one of the research studies, you must first agree to take part in
this screening study, which will be used to determine if you are eligible. After
participating in this study, you may be assigned to a study that is using an investigational
drug. The investigational drug(s) to be used in each of the 4 studies are not approved by
the Food and Drug Administration (FDA) for commercial use in this setting; however, the FDA
has permitted its use in these research studies.

If you agree to participate in this screening study, your complete medical history
(including smoking history) will be recorded and you will have a physical exam, including
measurement of vital signs (blood pressure, pulse, temperature, and breathing rate), height,
and weight. You will have blood (about 2 teaspoons) drawn for routine tests. You will also
have blood (about 1-2 tablespoons) drawn to check your blood clotting function, thyroid
function, and lipid (fat) levels. You will have a urine test, a performance status
evaluation (questions about your ability to perform everyday activities), and an
electrocardiogram (ECG -- a test that measures the electrical activity of the heart).

Your tumor will be evaluated by chest x-ray and computed tomography (CT) or magnetic
resonance imaging (MRI) scans to evaluate the status of the disease. You will have a brain
MRI. Women who are able to have children must have a negative blood (about 1 teaspoon)
pregnancy test before receiving the study drug.

A sample of your tumor tissue will be collected for biomarker analysis. If your tumor
tissue cannot be reached, you will not be able to participate in this research study. To
collect a tumor biopsy, you will have either a CT-guided core biopsy, bronchoscopy, or other
type of biopsy (such as subcutaneous, cutaneous, or lymph node). You will be asked to stop
taking any medication that affects blood-clotting (such as aspirin or coumadin) before the
biopsy procedure.

For the cutaneous (skin) biopsy, you will be given a local anesthetic by either a spray or
shot to numb your skin. A small cut will be made to remove all or a piece of the affected

For the CT-guided core biopsy of the lung, subcutaneous, and/or lymph node biopsy, a tissue
sample is withdrawn from an organ or suspected tumor mass using a very thin needle and a
syringe. The needle is guided while being viewed by the physician on a CT scan. Any site
that can be safely biopsied will be considered for the collection of tissue. Sites not
commonly biopsied include kidneys, adrenal glands, and brain.

For the bronchoscopy, you will be given drugs to relax, and then a local anesthetic will be
sprayed into your nose and throat to numb those areas. A slim, flexible tube with a light
will be placed through your nose or mouth and into your lungs. A small brush will be fed
through the tube and into your lungs. The brush will gently scrape off a sample of lung
tissue. Tweezers will then be fed through the tube to collect the tissue samples (biopsy).
A small amount of water will be sprayed into your lungs and then suctioned out through the
tube to collect tissue samples and mucous samples.

For the CT-guided core biopsy or bronchoscopy, you should not take any medications by mouth
or have any solid food for at least 6 hours before the procedure. You also should not have
any liquids 2 hours before the procedure.

If you are eligible to take part in this study, you will be assigned to 1 of the 4 research
studies based on the results of your tumor analysis. You will be asked to read and sign a
separate informed consent to take part in one of the research studies.

You have the right to leave the study at any time. If you choose to stop participating in
this study, you should contact the study chair and/or research nurse. Your doctor may
decide to take you off this study if your medical condition gets worse and/or you are unable
to comply with study requirements.

This is an investigational study. Up to 250 patients will take part in this study. All
will be enrolled at M. D. Anderson.

Inclusion Criteria:

1. The patient has a diagnosis of pathologically confirmed NSCLC by tumor biopsy and/or
fine-needle aspiration

2. The patient has a diagnosis of either stage IIIB, stage IV, or advanced, incurable
NSCLC, and failed at least one front-line metastatic NSCLC chemotherapy regimen.
(Patients who have failed adjuvant or locally advanced therapy within 6 months are
also eligible to participate in study).

3. The patient has uni-dimensionally measurable NSCLC.

4. Karnofsky performance status >/= 60 or ECOG performance status 0-2

5. The patient has biopsy accessible tumor.

6. The patient has adequate hematologic function as defined by an absolute neutrophil
count (ANC) >/= 1,500/mm^3, platelet count >/= 100,000/mm^3, WBC >/= 3,000/ mm^3, and
hemoglobin >/= 9 g/dL.

7. The patient has adequate hepatic function as defined by a total bilirubin level 1.5 X the upper limit of normal, and alkaline phosphatase, AST or ALT upper limit of normal.

8. The patient has adequate renal function as defined by a serum creatinine level 1.5 mg/dL or a calculated creatinine clearance of >/= 60cc/minute.

9. The patient has PT < 1.5 x upper limit of normal

10. If patient has brain metastasis, they must have been stable (treated or asymptomatic)
for at least 4 weeks after radiation if treated with radiation and not have used
steroids for at least 1 week. Re-imaging performed after 2 weeks, upon completion of
radiation therapy.

11. The patient is >/= 18 years of age.

12. The patient has signed informed consent.

13. The patient is eligible if disease free from a previously treated malignancy, other
than a previous NSCLC, for greater than two years. Patients with a history of prior
basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix are exempt
from exclusion.

14. Women of childbearing potential must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation. Childbearing potential will be defined as women who
have had menses within the past 12 months,who have not had tubal ligation or
bilateral oophorectomy.Should a woman become pregnant or suspect that she is pregnant
while participating in this study,she should inform her treating physician
immediately.The patient,if a man,agrees to use effective contraception or abstinence.

15. Subject must be considered legally capable of providing his or her own consent for
participation in this study.

Exclusion Criteria:

1. The patient has received prior investigational therapy, chemotherapy, surgery, or
radiotherapy within 4 weeks of initiating study drug

2. The patient has undergone prior thoracic or abdominal surgery within 28 days of study
entry, excluding prior diagnostic biopsy.

3. The patient has received radiation therapy to the measurable tumor within 6 months.
Patients are allowed to have local irradiation for the management of tumor-related
symptoms (bones, brain). However, if a patient has active new disease growing in the
previously irradiated site, the patient will be eligible to participate in the study.

4. The patient has a significant medical history or unstable medical condition (unstable
systemic disease: congestive heart failure (New York Heart Association Functional
Classification class II or worse), recent myocardial infarction within 3 months,
unstable angina, active infection (i.e. currently treated with antibiotics),
uncontrolled hypertension). Patients with controlled diabetes will be allowed.
Patient must be able to undergo procedure for tissue acquisition.

5. The patient has uncontrolled seizure disorder, active neurologic disease, or
neuropathy >/= grade 2. Patients with meningeal or CNS involvement by tumor are
eligible for the study if the above exclusion criteria are not met.

6. The patient is pregnant (confirmed by serum Beta-HCG if applicable) or is

7. Any condition that is unstable or could jeopardize the safety of the patient and its
compliance in the study, in the investigator's judgment.

8. The patient is actively taking herbal remedies or over-the-counter biologics (e.g.,
shark cartilage, high dose antioxidants).

9. Patients will be allowed to have prior biologic (i.e. VEGF, EGFR, etc.) therapy.
However, the patient will be excluded from a given study if he/she has received the
same therapy as the clinical trial (i.e. If a patient has been previously treated
with bevacizumab, they are allowed to enroll in any of the 4 studies. If a patient
has been previously treated with erlotinib, they are excluded from the clinical
trials with erlotinib). In addition, if a patient has been previously treated with
gefitinib (Iressa), they are excluded from the clinical trials with erlotinib.

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Biomarker Profile Assessment (before randomized allocation to research study)

Outcome Time Frame:

At enrollment

Safety Issue:


Principal Investigator

William N. William Jr., MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

November 2006

Completion Date:

Related Keywords:

  • Lung Cancer
  • Lung Cancer
  • Non Small Cell Lung Cancer
  • BATTLE Program
  • Umbrella Trial
  • Tumor Biopsy
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms



UT MD Anderson Cancer Center Houston, Texas  77030